Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
MgShell S.r.l. logo — La sfida che ci proponiamo è quella di rivoluzionare complet...

MgShell S.r.l.

La sfida che ci proponiamo è quella di rivoluzionare completamente l'approccio terapeutico nel campo oftalmico.

Founded 2019 Italy Italy 5 employees Seed Total: $500.00K Health Care, Manufacturing +1

General Information

Company Name MgShell S.r.l.
Founded Year 2019
Location Italy Italy +4
Founders / Decision Makers
Team member Team member
Employees 5
Industries Health Care, Manufacturing, Medical Devices
Funding Stage Seed
Social

Get notified when MgShell S.r.l. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MgShell S.r.l.

MgShell is an Italian startup founded in 2019, aiming to revolutionize the therapeutic approach in the field of ophthalmology. The company addresses the challenges associated with age-related macular degeneration, a chronic ocular disease and a leading cause of blindness in developed countries. With 500,000 new cases per year and an estimated 260 million affected patients by 2040, there is a pressing need for effective solutions. The current clinical strategy involves monthly intravitreal injections, which often result in a high rate of treatment dropout and pose a significant risk of irreversible blindness. In response, MgShell is developing an innovative intraocular device that aims to significantly reduce the number of injections and therapeutical burdens. This device represents a technological breakthrough, offering the ability to replicate the current clinical practice with a single injection, release therapeutic drug doses autonomously, and eliminate the need for surgical procedures. The latest milestone for MgShell was a €500.00K Seed Round investment on 26 January 2023, with financial backing from Club degli Investitori, Bios Line Holding, and Italian Angels for Biotech. The company operates in the Health Care and Manufacturing industries. MgShell's business model not only aims to improve compliance for affected patients but also seeks to reduce overheads for healthcare systems and create opportunities for pharmaceutical companies.

Taxonomy: Ophthalmic healthcare, Medical devices, Innovation, Therapeutic technology, Macular degeneration, Intraocular device, Drug delivery system, Pharmaceutical industry, Compliance solutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 3
Investor Investor Investor
26 Jan 2023
Seed Round •••••• 1 •••• •••• 01 Mar 2021

MgShell S.r.l. Alternatives & Competitors

MgShell S.r.l. vs
Adverum Biotechnologies
Adverum Biotechnologies United States

We are on a global mission to establish gene therapy as a new standard of care for the leading cause...

Acquired
133 employees
Biotechnology, Health and Wellness
MgShell S.r.l. vs
Re-Vana Therapeutics
Re-Vana Therapeutics United Kingdom

To advance the quality of care for patients suffering from sight-threatening diseases.

Series A
23 employees
Health Care, Health and Wellness
MgShell S.r.l. vs
Kinarus Therapeutics
Kinarus Therapeutics Switzerland

Kinarus Therapeutics is a clinical-stage company developing therapies for viral, respiratory and ocu...

Post Ipo Equity
5 employees
Biopharma, Biotechnology

FAQ About MgShell S.r.l.

La sfida che ci proponiamo è quella di rivoluzionare completamente l'approccio terapeutico nel campo oftalmico.
MgShell S.r.l. was founded in 2019.
MgShell S.r.l. is headquartered in Italy.
MgShell S.r.l. operates in the following industries: Health Care, Manufacturing, Medical Devices.
MgShell S.r.l. has approximately 5 employees.
MgShell S.r.l. has completed 2 funding rounds, raising a total of $500.00K. The latest funding stage is Seed.
Top alternatives and competitors to MgShell S.r.l. include Adverum Biotechnologies, Re-Vana Therapeutics, Kinarus Therapeutics, Lumos Pharma, Chase Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MgShell S.r.l. and Adverum Biotechnologies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MgShell S.r.l. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy